We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018 , the Compensation Committee of Sage’s
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018 , the Compensation Committee of Sage’s
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018 , the Compensation Committee of
Results from pivotal trials consistently showed treatment with brexanolone injection provided significant and rapid reduction in depressive symptoms within days of initiating therapy Treatment response was durable over the follow-up period, across three placebo-controlled trials ZULRESSO™
Conditional acceptance granted by U.S. Food and Drug Administration ( FDA ) for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone Continuing to execute commercial build and launch readiness for ZULRESSO™ (brexanolone injection) in postpartum depression ahead of PDUFA
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018 , the Compensation Committee of Sage’s
